Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BAT8007 in Advanced Solid Tumors
NCT05879627Phase 1Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jan 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8007 in solid tumor (advanced stage) and urothelial carcinoma (UC) (8 cohorts), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events. Started Jan 2023; status: terminated.
02
Drugs
BAT8007
03
Conditions
solid tumor (advanced stage)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05879627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879627.